Eyebright Medical Technology (Beijing) Co., Ltd.

XSSC:688050 Stock Report

Market Cap: CN¥17.1b

Eyebright Medical Technology (Beijing) Valuation

Is 688050 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688050 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688050 (CN¥90.28) is trading above our estimate of fair value (CN¥9.6)

Significantly Below Fair Value: 688050 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688050?

Key metric: As 688050 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688050. This is calculated by dividing 688050's market cap by their current earnings.
What is 688050's PE Ratio?
PE Ratio46.3x
EarningsCN¥369.60m
Market CapCN¥17.11b

Price to Earnings Ratio vs Peers

How does 688050's PE Ratio compare to its peers?

The above table shows the PE ratio for 688050 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.1x
688016 Shanghai MicroPort Endovascular MedTech
19.4x20.3%CN¥12.8b
300595 Autek China
25.9x16.8%CN¥16.9b
600529 Shandong Pharmaceutical GlassLtd
18.4x18.4%CN¥16.3b
688029 Micro-Tech (Nanjing)Ltd
24.6x19.0%CN¥13.5b
688050 Eyebright Medical Technology (Beijing)
46.3x30.5%CN¥17.1b

Price-To-Earnings vs Peers: 688050 is expensive based on its Price-To-Earnings Ratio (46.3x) compared to the peer average (22.1x).


Price to Earnings Ratio vs Industry

How does 688050's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
688050 46.3xIndustry Avg. 34.9xNo. of Companies18PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 688050 is expensive based on its Price-To-Earnings Ratio (46.3x) compared to the CN Medical Equipment industry average (34.6x).


Price to Earnings Ratio vs Fair Ratio

What is 688050's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688050 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46.3x
Fair PE Ratio35.4x

Price-To-Earnings vs Fair Ratio: 688050 is expensive based on its Price-To-Earnings Ratio (46.3x) compared to the estimated Fair Price-To-Earnings Ratio (35.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688050 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥90.28
CN¥125.50
+39.0%
3.6%CN¥130.00CN¥121.00n/a2
Nov ’25CN¥93.12
CN¥125.50
+34.8%
3.6%CN¥130.00CN¥121.00n/a2
Oct ’25CN¥99.40
CN¥125.50
+26.3%
3.6%CN¥130.00CN¥121.00n/a2
Sep ’25CN¥78.92
CN¥115.80
+46.7%
12.3%CN¥130.00CN¥96.39n/a3
Aug ’25CN¥79.14
CN¥119.17
+50.6%
13.6%CN¥133.33CN¥96.39n/a3
Jul ’25CN¥72.50
CN¥119.17
+64.4%
13.6%CN¥133.33CN¥96.39n/a3
Jun ’25CN¥76.10
CN¥119.17
+56.6%
13.6%CN¥133.33CN¥96.39n/a3
May ’25CN¥82.64
CN¥119.17
+44.2%
13.6%CN¥133.33CN¥96.39n/a3
Apr ’25CN¥73.42
CN¥123.98
+68.9%
17.1%CN¥147.78CN¥96.39n/a3
Mar ’25CN¥92.59
CN¥123.98
+33.9%
17.1%CN¥147.78CN¥96.39n/a3
Feb ’25CN¥74.47
CN¥125.99
+69.2%
14.7%CN¥147.78CN¥102.43n/a3
Jan ’25CN¥95.58
CN¥125.99
+31.8%
14.7%CN¥147.78CN¥102.43n/a3
Dec ’24CN¥109.17
CN¥130.50
+19.5%
16.4%CN¥147.78CN¥100.38n/a3
Nov ’24CN¥99.76
CN¥129.01
+29.3%
15.9%CN¥147.78CN¥100.38CN¥93.123
Oct ’24CN¥99.91
CN¥129.01
+29.1%
15.9%CN¥147.78CN¥100.38CN¥99.403
Sep ’24CN¥91.78
CN¥129.01
+40.6%
15.9%CN¥147.78CN¥100.38CN¥78.923
Aug ’24CN¥110.04
CN¥140.46
+27.6%
6.7%CN¥149.44CN¥127.49CN¥79.143
Jul ’24CN¥114.07
CN¥137.01
+20.1%
7.4%CN¥149.44CN¥126.67CN¥72.504
Jun ’24CN¥114.14
CN¥137.01
+20.0%
7.4%CN¥149.44CN¥126.67CN¥76.104
May ’24CN¥119.78
CN¥134.53
+12.3%
7.8%CN¥149.44CN¥126.67CN¥82.643
Apr ’24CN¥109.07
CN¥138.05
+26.6%
8.2%CN¥149.44CN¥126.67CN¥73.422
Mar ’24n/a
CN¥138.05
0%
8.2%CN¥149.44CN¥126.67CN¥92.592
Feb ’24n/a
CN¥138.05
0%
8.2%CN¥149.44CN¥126.67CN¥74.472
Jan ’24n/a
CN¥138.05
0%
8.2%CN¥149.44CN¥126.67CN¥95.582
Dec ’23n/a
CN¥133.05
0%
8.8%CN¥149.44CN¥123.05CN¥109.173
Nov ’23n/a
CN¥124.63
0%
14.2%CN¥149.44CN¥99.35CN¥99.764

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies